EXEL vs TNGX
EXEL: Exelixis is a commercial-stage oncology biotechnology company with a strong focus on developing small-molecule treatments for various types of cancer. TNGX: A precision oncology firm using a proprietary functional genomics platform to discover and develop targeted small-molecule therapies for genetically defined cancers.
Side-by-side fundamentals
| Metric | EXEL | TNGX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $59.02 | $22.57 | |
| Market cap | $14.6B | $3.8B | |
| P/E as of 2026-10-08 | 18.54 | n/a | |
| PEG as of 2026-10-08, 1-year EPS growth to FY2026 | 0.32 | n/a | |
| Net margin | +33.7% | -162.9% | EXEL higher |
| Operating margin | +37.6% | -178.4% | EXEL higher |
| ROE | +36.2% | -29.3% | EXEL higher |
| ROA | +27.5% | -25.5% | EXEL higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-03 | +9.2% | +39.0% | TNGX higher |
| Revenue CAGR (3y) SEC XBRL | +9.5% | +35.9% | TNGX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.55 | 1.33 | |
| 1-year return as of 2026-10-08 close | +52.7% | +226.6% | TNGX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.